Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
The OPTASE range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Cetirizine is used for relief of symptoms of hay fever and other allergic conditions
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Pfizer's decision is based on the totality of clinical data
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
The exclusive hospital will help address health complexities concerning women and children, specializing in high-end obstetrics, comprehensive gynecological, neonatal & pediatric care
Subscribe To Our Newsletter & Stay Updated
